Bio-Path (NASDAQ:BPTH) Rating Reiterated by Roth Mkm

Bio-Path (NASDAQ:BPTH)‘s stock had its “buy” rating reaffirmed by stock analysts at Roth Mkm in a research note issued to investors on Thursday, Benzinga reports. They presently have a $40.00 price objective on the stock.

Separately, StockNews.com began coverage on Bio-Path in a report on Tuesday. They issued a “sell” rating for the company.

Bio-Path Stock Up 2.1 %

Bio-Path stock opened at $4.29 on Thursday. The business has a 50 day moving average price of $5.40 and a two-hundred day moving average price of $8.51. The stock has a market cap of $2.91 million, a price-to-earnings ratio of -0.11 and a beta of 0.35. Bio-Path has a 12 month low of $2.70 and a 12 month high of $44.80.

Bio-Path (NASDAQ:BPTH) last issued its earnings results on Friday, March 8th. The company reported ($5.40) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($5.40). During the same period last year, the firm earned ($10.60) earnings per share. On average, analysts expect that Bio-Path will post -18.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bio-Path

Hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in Bio-Path during the 1st quarter valued at $38,000. Citadel Advisors LLC acquired a new stake in Bio-Path during the 3rd quarter valued at $35,000. Renaissance Technologies LLC acquired a new stake in Bio-Path during the 2nd quarter valued at $70,000. Walleye Capital LLC acquired a new stake in Bio-Path during the 3rd quarter valued at $77,000. Finally, Vanguard Group Inc. increased its holdings in Bio-Path by 77.5% during the 4th quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock valued at $125,000 after purchasing an additional 117,914 shares in the last quarter. 5.74% of the stock is owned by institutional investors and hedge funds.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.